SBL
NAUT icon

Sargent Bickham Lagudis’s Nautilus Biotechnolgy NAUT Stock Holding History

Sargent Bickham Lagudis’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$765 Hold
425
– – ﹤0.01% 978
2022
Q3 		$1K Hold
425
– – ﹤0.01% 936
2022
Q2 		$1K Buy
+425
New +$1.58K ﹤0.01% 999

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Sargent Bickham Lagudis's NAUT Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Nautilus Biotechnolgy (NAUT) position steady in Q4 2022 at 425 shares worth $765. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Sargent Bickham Lagudis first reported a position in NAUT in Q2 2022 and has held it in 3 quarters since. The position peaked at $1K in Q3 2022. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

  • Sargent Bickham Lagudis held 425 shares of Nautilus Biotechnolgy worth $765 as of Q4 2022.
  • Sargent Bickham Lagudis left its Nautilus Biotechnolgy share count unchanged in Q4 2022.
  • Nautilus Biotechnolgy made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #978 holding.
  • Sargent Bickham Lagudis first reported a position in Nautilus Biotechnolgy in Q2 2022 and has held it in 3 quarters since.
  • Sargent Bickham Lagudis's Nautilus Biotechnolgy position peaked at $1K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.